Synthego

Overview

Synthego, based in Redwood City, California, is a genome engineering company specializing in CRISPR solutions that enable accelerated life science research and therapeutic development. Founded in 2012 by Paul and Michael Dabrowski, former SpaceX engineers, Synthego has established itself as a leader in precision genome engineering, leveraging machine learning and automation to drive advancements in biotechnology. To date, the company has raised approximately $472.25 million over several funding rounds.

Recent Developments

  • In May 2025, Synthego filed for bankruptcy, planning to sell itself to its main lender, an affiliate of private equity firm Perceptive Advisors. This decision was driven by significant financial struggles, including a substantial debt burden and revenue challenges (Bloomberg).
  • Earlier in 2025, Synthego secured a strategic licensing agreement with AstraZeneca to manufacture and distribute a novel CRISPR gene editing enzyme, highlighting the company's continued focus on expanding its CRISPR capabilities despite financial setbacks (PRNewswire).
  • In March 2024, Synthego spun off its Engineered Cells division into a new entity, EditCo Bio, to focus on its core gRNA reagents business. This strategic move was part of its efforts to streamline operations and reduce losses (Bondoro).
  • Throughout 2024 and 2023, Synthego faced a liquidity crisis due to an inability to generate sufficient cash flow to meet its financial obligations, culminating in its Chapter 11 filing (Hoodline).

Company Information

AttributeInformation
Founding Date2012
HeadquartersRedwood City, California, USA
FoundersPaul Dabrowski, Michael Dabrowski
Revenue$75 million (as of early 2025)
ProfitsN/A
Key InvestorsPerceptive Advisors, AAF Management Ltd., RA Capital Management
IndustryGenome Engineering, Biotechnology
Number of EmployeesApproximately 201

Early History

Synthego was established in 2012 by brothers Paul and Michael Dabrowski with a vision to revolutionize genome engineering. Drawing on their background at SpaceX, they aimed to integrate their engineering expertise into the burgeoning field of CRISPR technology. Starting from a modest setup, the company quickly gained traction by partnering with leading biotech firms and research institutions, propelling it to the forefront of genome editing innovation. Early success was bolstered by strategic investments and technological advancements that aligned with the growing demand for CRISPR-based research tools.

Company Profile and Achievements

Synthego's business model revolves around providing comprehensive genome engineering solutions. The company offers a range of products, including synthetic RNA designed for CRISPR applications, catering to both research and clinical markets. Synthego's major achievements include:

  • Expansion of Product Lines: Launching the CRISPRevolution portfolio that features cutting-edge synthetic RNAs for CRISPR editing.
  • Strategic Partnerships: Securing partnerships with major pharmaceutical companies like AstraZeneca to license advanced CRISPR technologies.
  • Infrastructure Development: Establishing state-of-the-art manufacturing facilities to enhance production capabilities for synthetic sgRNAs.
  • Innovative Platforms: The development of platforms such as the Halo and Eclipse, which have significantly advanced genome engineering capabilities.

Current Operations and Market Position

Synthego continues to operate within the genome engineering sector, focusing primarily on providing CRISPR solutions to pharmaceutical, biotechnology companies, and academic institutions. The company maintains a strong presence in research and development, driven by its vertical integration of proprietary bioinformatics, software, and hardware. Despite recent financial struggles that led to its bankruptcy filing, Synthego remains a pivotal player in the biotechnology landscape, leveraging its advanced CRISPR platforms to sustain its market position.

Conclusion

Synthego has played a significant role in advancing the field of genome engineering, particularly with its contributions to CRISPR technology. Despite facing financial difficulties, the company's strategic initiatives and partnerships underscore its commitment to innovation and leadership in biotechnology. As Synthego navigates its restructuring phase, its foundational strengths in technology and collaboration are likely to guide its future trajectory in the genome engineering industry.

References

  1. Bloomberg
  2. PRNewswire
  3. Bondoro
  4. Hoodline
  5. Synthego - Overview
  6. Crunchbase
  7. CB Insights
  8. Notice.co
  9. Mercury News
  10. SFGate